Cytoplasmic PD-L1 Profiling for Cancer Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting patient response to cancer therapies, particularly immunotherapies and DDR inhibitors, are unreliable, and there is a need for personalized treatment approaches that account for tumor-specific biomarkers beyond BRCA1 status.
Innovation Solution
The use of cytoplasmic PD-L1 expression levels and downstream signaling, such as mTORC1 activation, to predict cancer treatment responses and patient prognosis, and the application of DDR inhibitors like Chk1i, ATMi, and PARPi based on PD-L1 depletion in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If surface PD-L1 expression is used to predict immunotherapy response, then the prediction is based on conventional biomarker assessment, but the prediction reliability is insufficient and controversial
Solution Approach 1:
The invention segments PD-L1 measurement into two distinct components: surface PD-L1 (measured by IHC) and cytoplasmic PD-L1 (measured by flow cytometry after cell lysis). This segmentation reveals that surface PD-L1 alone is insufficient for reliable prediction, while cytoplasmic PD-L1 provides superior predictive accuracy for immunotherapy response. The segmentation principle resolves the contradiction by identifying that the previously unmeasured cytoplasmic compartment contains the reliable biomarker signal.
Solution Approach 2:
The invention transitions from a two-dimensional surface measurement (IHC on tissue sections) to a three-dimensional intracellular measurement (flow cytometry detecting cytoplasmic PD-L1). This dimensional change enables detection of PD-L1 that was previously inaccessible, providing a more comprehensive and reliable prediction of immunotherapy response that overcomes the limitations of surface-only assessment.
2Ease of manufacture
If conventional IHC methods are used to measure PD-L1, then the measurement is standardized and widely applicable, but the measurement precision for predicting treatment response is insufficient
Solution Approach 1:
The invention merges two measurement approaches: conventional IHC for surface PD-L1 (maintaining accessibility) and flow cytometry for cytoplasmic PD-L1 (providing precision). By combining these methods in a sequential workflow, the invention achieves both ease of implementation and high prediction accuracy. The IHC provides initial screening and context, while flow cytometry delivers precise quantification of the predictive biomarker.
Solution Approach 2:
The invention introduces an intermediary step between conventional IHC and final prediction: flow cytometry-based cytoplasmic PD-L1 measurement. This intermediary measurement acts as a mediator that translates the complex intracellular PD-L1 status into a quantifiable metric that precisely predicts immunotherapy response, bridging the gap between accessible conventional methods and precise prediction requirements.
3Device complexity
If PD-L1 expression is measured without distinguishing cytoplasmic and surface locations, then the measurement process is simplified, but the prediction of treatment response and patient survival is inaccurate
Solution Approach 1:
The invention segments the PD-L1 measurement process into distinct steps: first measuring surface PD-L1 by IHC, then measuring cytoplasmic PD-L1 by flow cytometry. This segmentation, while increasing procedural steps, enables accurate distinction between the two compartments. The segmentation resolves the contradiction by demonstrating that the additional measurement complexity is necessary and justified by the significant improvement in prognostic accuracy.
Solution Approach 2:
The invention introduces dynamic adaptability to the measurement process: the decision to perform flow cytometry follows IHC results, and the interpretation of total PD-L1 status dynamically integrates both surface and cytoplasmic measurements. This dynamic approach optimizes the balance between complexity and accuracy by adapting the measurement depth to each patient's specific tumor characteristics.
Data Source
AI summary
Provided herein are methods for the diagnosis, assessment, and treatment of cancer. In some aspects, detection of intracellular or cytoplasmic PD-L1, or measuring the ratio of cytoplasmic to surface PD-L1, can be used to identify cancers that may respond to immunotherapies or a DDR inhibitor such as, e.g., a Chk1 inhibitor, a PARP inhibitor, an ATM inhibitor, or an ATR inhibitor.